Potassium 2,2'-(piperazine-1,4-diyl)diethanesulfonate

Catalog No. :
ACOIVC314
CAS No. :
108321-27-3
Molecular Formula :
C8H16K2N2O6S2
Molecular Weight :
378.55

IUPAC Name:potassium 2,2'-(piperazine-1,4-diyl)bis(ethane-1-sulfonate)

Potassium 2,2'-(piperazine-1,4-diyl)diethanesulfonate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100g95%$72.00Login to see priceIn stockInquiry
500g95%$291.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product NamePotassium 2,2'-(piperazine-1,4-diyl)diethanesulfonate
IUPAC Namepotassium 2,2'-(piperazine-1,4-diyl)bis(ethane-1-sulfonate)
MDL No.MFCD00069751
Molecular FormulaC8H16K2N2O6S2
Molecular Weight378.55
SMILESO=S(CCN1CCN(CCS(=O)([O-])=O)CC1)([O-])=O.[K+].[K+]
InChI KeyBJQYFCAMUXGZFN-UHFFFAOYSA-L
SynonymPiperazine-1,4-bis(2-ethanesulfonic acid)dipotassium salt | 1,4-Piperazinediethanesulfonic acid, potassium salt (1:2) | PIPES dipotassium salt | SCHEMBL9897196 | MFCD00069751 | AKOS024464834 | 1,4-Piperazinediethanesulfonic acid, dipotassium salt | PIPES
CAS No.108321-27-3
PubChem CID176078

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACOIVC314 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOIVC314 route product structure diagram
    ACOIVC314108321-27-3 In Stock
Inquiry

2. ACOIVC314 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACOIVC314 route product structure diagram
    ACOIVC314108321-27-3 In Stock
Inquiry

Comments (0)